The anti-depressant Prozac may slow down the development of multiple sclerosis, according to a study of 38 patients by researchers at Groningen University.

The findings are reported in a British Medical Journal publication on Thursday.
Half the patients on the trial were given a placebo, the rest Prozac. At the end of the 24-week test period, two-thirds of those given Prozac had not developed any new brain lesions, compared with 25% of those not taking the drug.
One million people worldwide suffer from MS which has no cure. The researchers say the results are enough to merit further research.